Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease

Journal of Internal Medicine

Volumn 239, Issue 3, 1996, Pages 227-233

  Carlsen, S M ^a   Rossvoll, O ^a   Bjerve, K S ^a   Folling I ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cholesterol; Coronary heart disease; Lovastatin; Metformin; Weight

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MEVINOLIN; ORGANIC NITRATE;

ADJUVANT THERAPY; ADULT; ARTICLE; BODY WEIGHT; CLINICAL PROTOCOL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIARRHEA; DIET; DRUG EFFECT; FLATULENCE; HUMAN; LIFESTYLE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL;

EID: 0030052398     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1996.444790000.x     Document Type: Article

References (28)

1. Brown BG, Zhao X-Q, Sacco DE, Albers JJ. Lipid-lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993: 87: 1781-91.
2. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA et al. Can lifestyle changes reverse coronary heart disease? The lifestyle heart trial. Lancet 1990; 356: 129-33.
3. The Scandinavian simvastatin study group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994; 344: 1383-9.
4. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LDR et al. Effect on coronary artery disease of lipid-lowering diet, or diet plus cholestyamine, in the St Thomas atherosclerosis regression study (STARS). Lancet 1992: 339: 563-9.
5. Bradford RH, Shear CL, Chremos AN, Franklin FA, Nash DT, Hurley DP et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy of modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991: 151: 43-9.
6. Pierce LR, Wysowski DK, Gross TP. Myopathi and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990: 264: 71-5.
7. Reaven P, Witztum JL. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med 1988: 109: 597-8.
8. Uusitupa M, Ebling T, Happonen P, Voutilainen E, Turtola H, Parviainen M et al. Combination therapy with lovastatin and guar gum versus lovastatin and cholestyramin in treatment of hypercholesterolemia. J Cardiovasc Pharmacol 1991: 18: 496-503.
9. Glueck CJ, Oakes N, Speirs J, Tracy T, Lang J. Gemfibrozillovastatin therapy for primary hyperlipoproteinemias. Am J Cardiol 1992: 70: 1-9.
10. Bailey CJ. Metformin revisited: its actions and indications for use. Diabetic Med 1988: 5: 315-20.
11. Hermann LS, Karlsson JE, Sjøstrand Å. Prospective comparative study in NIDDM patients of metformin and gibenclamide with special reference to lipid profiles. Eur J Clin Pharmacol 1991: 41: 263-5.
12. Elkeles RS. The effects of oral hypoglycemic drugs on serum lipids and lipoproteins in non-insulin-dependent diabetes (NIDDM). Diabete Metab 1991; 17: 197-200.
13. Pentikainen PJ, Voutilainen E, Aro A, Uusitupa M, Pentilla I, Vapaatalo H. Cholesterol lowering effect of metformin in combined hyperlipidemia: placebo controlled double blind trial. Annals of Medicine 1990: 22: 307-12.
14. Sirtori CR, Lovati MR, Franceschini G. Management of lipid disorders and prevention of atherosclerosis with metformin. A research and clinical update. RSM International Congress and Symposium Series 79. London: Royal Society of Medicine, 1985: 33-44.
15. Giugliano D, De Rosa N, Di Maro G, Marfella R, Acampora R, Buoninconti R et al. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 1993: 16: 1387-90.
16. De Silva SR, Betteridge DJ, Shawe JEH, Cudworth AG, Alberti KGMM. Metformin and clofibrate in maturity onset diabetes mellitus: advantages of combined treatment. Diabete Metab 1979; 5: 223-9.
17. Jeppsen J, Zhou M-Y, Chen Y-DI, Reaven GM. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care 1994: 17: 1093-9.
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 1972: 18: 499-502.
19. Marquie G. Effect of metformin on lipid metabolism in the rabbit aortic wall. Atherosclerosis 1978: 30: 165-75.
20. Marquie G. Metformin action on lipid metabolism in lesions of experimental aortic atherosclerosis of rabbits. Atherosclerosis 1983: 47: 7-17.
21. Charlon V, Boucher F, Mouhieddine S, De Leiris J. Reduction of myocardial infarct size by metformin in rats submitted to permanent left coronary artery ligation. Diabete Metab 1988; 14: 591-5.
22. Scott LM, Tomkin GH. Changes in hepatic and intestinal cholesterol regulatory enzymes. Biochem Pharmacol 1983: 32: 827-30.
23. Maziere JC, Maziere C, Mora L, Gerdette J, Salmon S, Auclair M et al. The antidiabetic drug metformin decreases cholesterol metabolism in human fibroblasts. Atherosclerosis 1988: 71: 27-33.
24. Hotta N, Mori K, Nakamura J, Koh N, Sakakibara F, Hamada Y. Effects of biguanides on alanine-induced lipid synthesis in hepatocytes of WKY-fatty rats. Diabetologia 1994: 37 (Suppl. 1): A62.
25. Wilcock C, Wyre ND, Bailey CJ. Subcellular distribution of metformin in rat liver. J Pharm Pharmacol 1991; 43: 442-4.
26. Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 1994; 24: 49-57.
27. Berchtold P, Bolli P, Arbenz U, Kaiser G. Intestinale Absopitonsstürung infolge Metforminbehandlung. (Zur frage der Wirkungsweise der Biguanide.) Diribetologia 1969; 5: 405-12.
28. Velazquez EM, Mendosa S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994; 43: 647-54.